Literature DB >> 19499188

The effect of cellular environment and p53 status on the mode of action of the platinum derivative LA-12.

Eva Roubalová1, Veronika Kvardová, Roman Hrstka, Sárka Borilová, Eva Michalová, Lenka Dubská, Petr Müller, Petr Sova, Borivoj Vojtesek.   

Abstract

In this study, we characterized the effects of LA-12 on tumor cell lines possessing wild type p53 and on p53-deficient/mutant cell lines and the results were compared to those obtained using cisplatin. We have determined changes of p53 levels, of its transcriptional activity, of its posttranscriptional modifications and the effect of the treatment on the cell cycle, on the induction of apoptosis and on gene expression. LA-12 induces weak accumulation of both transcriptionally active p53 tumor suppressor and of p21(WAF1/CIP1) protein. LA-12 and cisplatin also significantly differ in their effects on apoptosis and cell cycle and on gene expression spectra in studied cell lines. LA-12 induces higher apoptosis levels in comparison with those induced by cisplatin, especially in p53-deficient H1299 cells and in MCF-7DD cells with transcriptionally inactive p53. We suggest that LA-12-mediated apoptosis is not fully dependent on p53. This confirms the therapeutic potential of LA-12 as a more potent cytostatic agent for both tumor cells expressing wild type p53 and for p53-deficient or mutant cells.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19499188     DOI: 10.1007/s10637-009-9270-4

Source DB:  PubMed          Journal:  Invest New Drugs        ISSN: 0167-6997            Impact factor:   3.850


  32 in total

1.  High effectiveness of platinum(IV) complex with adamantylamine in overcoming resistance to cisplatin and suppressing proliferation of ovarian cancer cells in vitro.

Authors:  Alois Kozubík; Viktor Horváth; Lenka Svihálková-Sindlerová; Karel Soucek; Jirina Hofmanová; Petr Sova; Ales Kroutil; Frantisek Zák; Adolf Mistr; Jaroslav Turánek
Journal:  Biochem Pharmacol       Date:  2004-12-23       Impact factor: 5.858

2.  Transcriptional repression by the C-terminal domain of p53.

Authors:  E Shaulian; I Haviv; Y Shaul; M Oren
Journal:  Oncogene       Date:  1995-02-16       Impact factor: 9.867

3.  Neuromedin B is present in lung cancer cell lines.

Authors:  G Giaccone; J Battey; A F Gazdar; H Oie; M Draoui; T W Moody
Journal:  Cancer Res       Date:  1992-05-01       Impact factor: 12.701

4.  Up-regulation of Fas (CD95) in human p53wild-type cancer cells treated with ionizing radiation.

Authors:  M A Sheard; B Vojtesek; L Janakova; J Kovarik; J Zaloudik
Journal:  Int J Cancer       Date:  1997-11-27       Impact factor: 7.396

Review 5.  Post-translational modification of p53 in tumorigenesis.

Authors:  Ann M Bode; Zigang Dong
Journal:  Nat Rev Cancer       Date:  2004-10       Impact factor: 60.716

Review 6.  DNA modifications by antitumor platinum and ruthenium compounds: their recognition and repair.

Authors:  Viktor Brabec
Journal:  Prog Nucleic Acid Res Mol Biol       Date:  2002

7.  Platinum(IV) complex with adamantylamine as nonleaving amine group: synthesis, characterization, and in vitro antitumor activity against a panel of cisplatin-resistant cancer cell lines.

Authors:  Frantisek Zák; Jaroslav Turánek; Ales Kroutil; Petr Sova; Adolf Mistr; Anna Poulová; Petr Mikolin; Zdirad Zák; Andrea Kasná; Dana Záluská; Jirí Neca; Lenka Sindlerová; Alois Kozubík
Journal:  J Med Chem       Date:  2004-01-29       Impact factor: 7.446

8.  An immunochemical analysis of the human nuclear phosphoprotein p53. New monoclonal antibodies and epitope mapping using recombinant p53.

Authors:  B Vojtĕsek; J Bártek; C A Midgley; D P Lane
Journal:  J Immunol Methods       Date:  1992-07-06       Impact factor: 2.303

9.  p53-dependent inhibition of cyclin-dependent kinase activities in human fibroblasts during radiation-induced G1 arrest.

Authors:  V Dulić; W K Kaufmann; S J Wilson; T D Tlsty; E Lees; J W Harper; S J Elledge; S I Reed
Journal:  Cell       Date:  1994-03-25       Impact factor: 41.582

10.  WAF1/CIP1 is induced in p53-mediated G1 arrest and apoptosis.

Authors:  W S el-Deiry; J W Harper; P M O'Connor; V E Velculescu; C E Canman; J Jackman; J A Pietenpol; M Burrell; D E Hill; Y Wang
Journal:  Cancer Res       Date:  1994-03-01       Impact factor: 12.701

View more
  7 in total

Review 1.  The lipophilic bullet hits the targets: medicinal chemistry of adamantane derivatives.

Authors:  Lukas Wanka; Khalid Iqbal; Peter R Schreiner
Journal:  Chem Rev       Date:  2013-02-25       Impact factor: 60.622

2.  Higher anti-tumour efficacy of platinum(IV) complex LA-12 is associated with its ability to bypass M-phase entry block induced in oxaliplatin-treated human colon cancer cells.

Authors:  O Vondálová Blanářová; I Jelínková; A Hyršlová Vaculová; P Sova; J Hofmanová; A Kozubík
Journal:  Cell Prolif       Date:  2013-09-30       Impact factor: 6.831

3.  The new platinum(IV) derivative LA-12 shows stronger inhibitory effect on Hsp90 function compared to cisplatin.

Authors:  Veronika Kvardova; Roman Hrstka; Dawid Walerych; Petr Muller; Eva Matoulkova; Veronika Hruskova; Dagmar Stelclova; Petr Sova; Borivoj Vojtesek
Journal:  Mol Cancer       Date:  2010-06-15       Impact factor: 27.401

4.  The new platinum-based anticancer agent LA-12 induces retinol binding protein 4 in vivo.

Authors:  Pavel Bouchal; Jiri Jarkovsky; Kristyna Hrazdilova; Monika Dvorakova; Iva Struharova; Lenka Hernychova; Jiri Damborsky; Petr Sova; Borivoj Vojtesek
Journal:  Proteome Sci       Date:  2011-10-31       Impact factor: 2.480

5.  Cisplatin or LA-12 enhance killing effects of TRAIL in prostate cancer cells through Bid-dependent stimulation of mitochondrial apoptotic pathway but not caspase-10.

Authors:  Olga Vondálová Blanářová; Barbora Šafaříková; Jarmila Herůdková; Martin Krkoška; Silvie Tománková; Zuzana Kahounová; Ladislav Anděra; Jan Bouchal; Gvantsa Kharaishvili; Milan Král; Petr Sova; Alois Kozubík; Alena Hyršlová Vaculová
Journal:  PLoS One       Date:  2017-11-28       Impact factor: 3.240

6.  Loss of PTEN Facilitates Rosiglitazone-Mediated Enhancement of Platinum(IV) Complex LA-12-Induced Apoptosis in Colon Cancer Cells.

Authors:  Jarmila Lauková; Alois Kozubík; Jiřina Hofmanová; Jana Nekvindová; Petr Sova; Mary Pat Moyer; Jiří Ehrmann; Alena Hyršlová Vaculová
Journal:  PLoS One       Date:  2015-10-22       Impact factor: 3.240

7.  Chk1 Inhibitor SCH900776 Effectively Potentiates the Cytotoxic Effects of Platinum-Based Chemotherapeutic Drugs in Human Colon Cancer Cells.

Authors:  Jarmila Herůdková; Kamil Paruch; Prashant Khirsariya; Karel Souček; Martin Krkoška; Olga Vondálová Blanářová; Petr Sova; Alois Kozubík; Alena Hyršlová Vaculová
Journal:  Neoplasia       Date:  2017-09-06       Impact factor: 5.715

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.